ECSP21031200A - USE OF REBOXETIN FOR THE TREATMENT OF NARCOLEPSY - Google Patents
USE OF REBOXETIN FOR THE TREATMENT OF NARCOLEPSYInfo
- Publication number
- ECSP21031200A ECSP21031200A ECSENADI202131200A ECDI202131200A ECSP21031200A EC SP21031200 A ECSP21031200 A EC SP21031200A EC SENADI202131200 A ECSENADI202131200 A EC SENADI202131200A EC DI202131200 A ECDI202131200 A EC DI202131200A EC SP21031200 A ECSP21031200 A EC SP21031200A
- Authority
- EC
- Ecuador
- Prior art keywords
- narcolepsy
- treatment
- reboxetin
- reboxetine
- cataplexy
- Prior art date
Links
- 201000003631 narcolepsy Diseases 0.000 title abstract 4
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 abstract 3
- 229960003770 reboxetine Drugs 0.000 abstract 3
- 208000023046 narcolepsy-cataplexy syndrome Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000001573 Cataplexy Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La patente consiste en métodos para el tratamiento de narcolepsia con cataplexia, que comprenden la administración de reboxetina a un ser humano que lo necesita. La reboxetina también se puede usar en la elaboración de un medicamento para el tratamiento de la narcolepsia con cataplexia. También se describen en el presente documento kits que comprenden una composición farmacéutica que comprende reboxetina e instrucciones para usar la composición farmacéutica para tratar la narcolepsia con cataplexia en un ser humano.The patent consists of methods for the treatment of narcolepsy with cataplexy, which comprise the administration of reboxetine to a human being in need. Reboxetine can also be used in the manufacture of a drug for the treatment of narcolepsy with cataplexy. Also described herein are kits comprising a pharmaceutical composition comprising reboxetine and instructions for using the pharmaceutical composition to treat cataplexy narcolepsy in a human.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862745956P | 2018-10-15 | 2018-10-15 | |
| PCT/US2019/056134 WO2020081461A1 (en) | 2018-10-15 | 2019-10-14 | Use of reboxetine to treat narcolepsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP21031200A true ECSP21031200A (en) | 2021-05-31 |
Family
ID=70284075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202131200A ECSP21031200A (en) | 2018-10-15 | 2021-04-30 | USE OF REBOXETIN FOR THE TREATMENT OF NARCOLEPSY |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP3866768A4 (en) |
| JP (2) | JP2022504975A (en) |
| KR (2) | KR20240119194A (en) |
| CN (1) | CN112888430A (en) |
| AU (3) | AU2019361915A1 (en) |
| BR (1) | BR112021007019A2 (en) |
| CL (1) | CL2021000924A1 (en) |
| CO (1) | CO2021004681A2 (en) |
| CR (1) | CR20210514A (en) |
| EC (1) | ECSP21031200A (en) |
| IL (2) | IL319177A (en) |
| MX (2) | MX2021004207A (en) |
| PE (1) | PE20211199A1 (en) |
| SG (1) | SG11202103588WA (en) |
| WO (1) | WO2020081461A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
| US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| WO2021113163A1 (en) * | 2019-12-03 | 2021-06-10 | Axsome Therapeutics, Inc. | Use of reboxetine to treat nervous system disorders |
| US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| KR102893312B1 (en) * | 2021-10-19 | 2025-12-01 | 단국대학교 천안캠퍼스 산학협력단 | Composition for preventing or treating sarcopenia comprising reboxetine as an active ingredient |
| WO2025207664A1 (en) * | 2024-03-25 | 2025-10-02 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| US12565478B1 (en) | 2025-01-21 | 2026-03-03 | Axsome Therapeutics, Inc. | (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6485746B1 (en) * | 2000-08-25 | 2002-11-26 | Neurocrine Biosciences, Inc. | Controlled-release sedative-hypnotic compositions and methods related thereto |
| US20030133982A1 (en) * | 2001-12-20 | 2003-07-17 | Heimlich John M. | Zero-order sustained release dosage forms and method of making same |
| MY136318A (en) * | 2002-07-25 | 2008-09-30 | Pharmacia Corp | Sustained-release tablet composition |
| US20080261984A1 (en) * | 2004-06-09 | 2008-10-23 | Pfizer Inc. | Use of S,S-Reboxetine in the Treatment of Pain |
| RU2689984C2 (en) * | 2013-03-13 | 2019-05-30 | ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи | Cataplexis treatment |
-
2019
- 2019-10-14 CR CR20210514A patent/CR20210514A/en unknown
- 2019-10-14 KR KR1020247025741A patent/KR20240119194A/en active Pending
- 2019-10-14 IL IL319177A patent/IL319177A/en unknown
- 2019-10-14 BR BR112021007019-2A patent/BR112021007019A2/en unknown
- 2019-10-14 MX MX2021004207A patent/MX2021004207A/en unknown
- 2019-10-14 PE PE2021000514A patent/PE20211199A1/en unknown
- 2019-10-14 EP EP19874099.5A patent/EP3866768A4/en active Pending
- 2019-10-14 IL IL282311A patent/IL282311B2/en unknown
- 2019-10-14 AU AU2019361915A patent/AU2019361915A1/en not_active Abandoned
- 2019-10-14 SG SG11202103588WA patent/SG11202103588WA/en unknown
- 2019-10-14 WO PCT/US2019/056134 patent/WO2020081461A1/en not_active Ceased
- 2019-10-14 KR KR1020217013455A patent/KR20210071046A/en not_active Ceased
- 2019-10-14 CN CN201980067756.9A patent/CN112888430A/en active Pending
- 2019-10-14 JP JP2021520615A patent/JP2022504975A/en active Pending
-
2021
- 2021-04-12 MX MX2025003477A patent/MX2025003477A/en unknown
- 2021-04-14 CO CONC2021/0004681A patent/CO2021004681A2/en unknown
- 2021-04-14 CL CL2021000924A patent/CL2021000924A1/en unknown
- 2021-04-30 EC ECSENADI202131200A patent/ECSP21031200A/en unknown
-
2023
- 2023-02-16 AU AU2023200917A patent/AU2023200917A1/en not_active Abandoned
-
2025
- 2025-02-23 AU AU2025201286A patent/AU2025201286A1/en active Pending
- 2025-06-10 JP JP2025096479A patent/JP2025134749A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3866768A1 (en) | 2021-08-25 |
| JP2025134749A (en) | 2025-09-17 |
| KR20240119194A (en) | 2024-08-06 |
| IL282311B1 (en) | 2025-04-01 |
| WO2020081461A1 (en) | 2020-04-23 |
| AU2023200917A1 (en) | 2023-03-23 |
| CN112888430A (en) | 2021-06-01 |
| IL319177A (en) | 2025-04-01 |
| CA3115983A1 (en) | 2020-04-23 |
| SG11202103588WA (en) | 2021-05-28 |
| BR112021007019A2 (en) | 2021-07-13 |
| JP2022504975A (en) | 2022-01-13 |
| EP3866768A4 (en) | 2022-01-05 |
| CO2021004681A2 (en) | 2021-06-21 |
| CL2021000924A1 (en) | 2021-09-03 |
| PE20211199A1 (en) | 2021-07-01 |
| AU2019361915A1 (en) | 2021-05-13 |
| IL282311A (en) | 2021-05-31 |
| MX2021004207A (en) | 2021-08-11 |
| IL282311B2 (en) | 2025-08-01 |
| MX2025003477A (en) | 2025-05-02 |
| AU2025201286A1 (en) | 2025-03-13 |
| CR20210514A (en) | 2021-11-12 |
| KR20210071046A (en) | 2021-06-15 |
| NZ775057A (en) | 2024-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21031200A (en) | USE OF REBOXETIN FOR THE TREATMENT OF NARCOLEPSY | |
| CO2022010330A2 (en) | Gamma-Hydroxybutyrate (GHB) Dosage | |
| MX2019010757A (en) | METHODS AND COMPOSITIONS RELATED TO THE COMBINED TREATMENT WITH ANTI-INFLAMMATORY AND SYNTHETIC NANPORTERS THAT INCLUDE AN IMMUNOSUPPRESSOR. | |
| MX2023000796A (en) | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATMENT AND ITS USES. | |
| CL2017002996A1 (en) | Tetra-substituted alkene compounds and their use | |
| BR112016027773A2 (en) | cell penetrating peptide, polynucleotide, recombinant botulinum toxin penetrating cell protein, recombinant expression vector, bacterium, pharmaceutical composition, cosmetic composition and method for producing a recombinant botulinum toxin cell penetrating protein | |
| DOP2018000297A (en) | DERIVATIVE OF GLUCAGON, CONJUGATE OF THE SAME, COMPOSITION THAT INCLUDES THE SAME AND THERAPEUTIC USE OF THE SAME | |
| GT201700246A (en) | METHODS AND KITS TO TREAT DEPRESSION | |
| BR112017006113A8 (en) | Auristatin uses, pharmaceutical compositions, dosage forms for cancer treatment and kits. | |
| MX2022014792A (en) | COCRYSTALS, PHARMACEUTICAL COMPOSITIONS THEREOF AND TREATMENT METHODS INVOLVING THEM. | |
| MX2019003134A (en) | Combination therapy. | |
| MX393613B (en) | GEL COMPOSITIONS FOR TRANSDERMAL DELIVERY TO MAXIMIZE DRUG CONCENTRATIONS IN THE STRATUM CORNEUM AND SERUM, AND METHODS OF USING SAME. | |
| CL2019002218A1 (en) | Triple combination formulations and methods to treat or reduce the risk of cardiovascular disease. | |
| MX2021007453A (en) | PERINEURAL ADMINISTRATION OF RESINIFERATOXIN FOR THE TREATMENT OF MALADAPTIVE PAIN. | |
| MX2018016332A (en) | Combination chemotherapies. | |
| MX394475B (en) | METHODS FOR THE TREATMENT OF INFLAMMATION-RELATED CONDITIONS USING PLURIPOTENT ANTI-INFLAMMATORY AND METABOLIC MODULATORS. | |
| MX2020007760A (en) | Compositions and methods of enhancing 5-hydroxytryptophan bioavailability. | |
| MX2021003263A (en) | Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer. | |
| MX2022014577A (en) | LEVODOPA AND CARBIDOPA INTESTINAL GEL AND METHODS OF USE. | |
| MX2022005358A (en) | Ph responsive block copolymer compositions, micelles, and methods of use. | |
| MX2016011025A (en) | GRAPIPRANT COMPOSITIONS AND METHODS TO USE THE SAME. | |
| CL2019003288A1 (en) | A pharmaceutical combination for the treatment of cancer. | |
| MX2021011334A (en) | Antibodies having specificity for btn2 and uses thereof. | |
| AR122344A1 (en) | USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS | |
| CO2022007507A2 (en) | Use of reboxetine to treat disorders of the nervous system |